SG11201903830TA - Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies - Google Patents

Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

Info

Publication number
SG11201903830TA
SG11201903830TA SG11201903830TA SG11201903830TA SG11201903830TA SG 11201903830T A SG11201903830T A SG 11201903830TA SG 11201903830T A SG11201903830T A SG 11201903830TA SG 11201903830T A SG11201903830T A SG 11201903830TA SG 11201903830T A SG11201903830T A SG 11201903830TA
Authority
SG
Singapore
Prior art keywords
international
rule
singapore
pct
applicant
Prior art date
Application number
SG11201903830TA
Other languages
English (en)
Inventor
Dario Campana
Natasha Vinanica
Takahiro Kamiya
Yi Png
Original Assignee
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore
Publication of SG11201903830TA publication Critical patent/SG11201903830TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201903830TA 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies SG11201903830TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425398P 2016-11-22 2016-11-22
US201762543696P 2017-08-10 2017-08-10
PCT/US2017/063048 WO2018098306A1 (en) 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

Publications (1)

Publication Number Publication Date
SG11201903830TA true SG11201903830TA (en) 2019-05-30

Family

ID=62193475

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903830TA SG11201903830TA (en) 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG10201912387PA SG10201912387PA (en) 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912387PA SG10201912387PA (en) 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

Country Status (9)

Country Link
US (4) US11440958B2 (enExample)
EP (1) EP3545082A4 (enExample)
JP (3) JP7778468B2 (enExample)
KR (2) KR102889007B1 (enExample)
CN (3) CN118562882B (enExample)
AU (3) AU2017363278B2 (enExample)
CA (1) CA3043752A1 (enExample)
SG (2) SG11201903830TA (enExample)
WO (1) WO2018098306A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392456B (es) 2014-01-31 2025-03-19 Monolith Mat Inc Soplete de plasma.
CN107709474A (zh) 2015-02-03 2018-02-16 巨石材料公司 炭黑生成系统
PL3253865T3 (pl) 2015-02-06 2022-10-10 National University Of Singapore Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych
CA3032246C (en) 2015-07-29 2023-12-12 Monolith Materials, Inc. Dc plasma torch electrical power design method and apparatus
KR20180094838A (ko) 2015-08-07 2018-08-24 모놀리스 머티어리얼스 인코포레이티드 카본 블랙의 제조 방법
CA3033947C (en) 2015-09-09 2024-05-28 Monolith Materials, Inc. Circular few layer graphene
CN109996811A (zh) 2016-08-03 2019-07-09 约翰·F·迪帕西奥 用于用嵌合抗原受体治疗t细胞恶性肿瘤的car-t细胞的基因编辑
JP7778468B2 (ja) 2016-11-22 2025-12-02 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断
WO2018237022A1 (en) 2017-06-21 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
SG11202000402PA (en) 2017-08-10 2020-02-27 Nat Univ Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
AU2019275076B2 (en) 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
US12227776B2 (en) 2018-06-13 2025-02-18 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US10227576B1 (en) * 2018-06-13 2019-03-12 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
CA3092709A1 (en) 2018-10-31 2020-05-07 Nantkwest, Inc. Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells
AU2019372673A1 (en) * 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
US20210395779A1 (en) 2018-11-14 2021-12-23 Medisix Therapeutics Pte Ltd. Two-gene vectors for generating car-t cells and uses thereof
CN109652379B (zh) * 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
JP7741732B2 (ja) 2019-05-07 2025-09-18 グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド Ｂｃｍａを標的とする操作された免疫細胞及びその使用
GB201914611D0 (en) * 2019-10-09 2019-11-20 Autolus Ltd Engineered immune cell
EP4041316A4 (en) * 2019-10-11 2023-10-11 The Board of Trustees of the Leland Stanford Junior University RECOMBINANT POLYPEPTIDES FOR REGULABLE CELL LOCALIZATION
CN120905142A (zh) * 2019-11-20 2025-11-07 卡瑟里克斯私人有限公司 用于提供具有增强功能的免疫细胞的方法
WO2021113853A1 (en) * 2019-12-05 2021-06-10 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
WO2021118873A1 (en) * 2019-12-09 2021-06-17 St. Jude Children's Research Hospital, Inc. Method for preparing cd7-negative, cd3-positive t cells
US12312407B2 (en) * 2020-01-30 2025-05-27 St Phi Therapeutics Co., Ltd. Universal T cells and the method of use thereof
CN112300282A (zh) * 2020-11-03 2021-02-02 南京北恒生物科技有限公司 靶向cd7的人源化抗体及其用途
CN120025983A (zh) * 2020-11-03 2025-05-23 南京北恒生物科技有限公司 靶向cd7的嵌合抗原受体及其用途
AU2021377699A1 (en) 2020-11-13 2023-06-15 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
CN114525306B (zh) * 2020-11-23 2025-01-28 博生吉医药科技(苏州)有限公司 一种cd7-car-t细胞的制备方法及应用
US20240269304A1 (en) 2020-11-24 2024-08-15 Novartis Ag Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN113234682B (zh) * 2021-01-12 2023-02-21 上海雅科生物科技有限公司 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用
EP4273175A4 (en) * 2021-02-03 2024-08-14 Bioheng Therapeutics Limited NOVEL CHIMERIC ANTIGEN RECEPTOR AND ITS USE
CN112980800A (zh) * 2021-03-08 2021-06-18 河北森朗生物科技有限公司 Car-t细胞、其构建方法及其应用
CN115044617B (zh) * 2021-03-08 2024-08-13 河北森朗生物科技有限公司 Car t细胞的制备方法、car t细胞及其应用
CN112662631B (zh) * 2021-03-16 2021-06-29 合源生物科技(天津)有限公司 一种car-t细胞灌流培养方法
AU2022262088A1 (en) 2021-04-22 2023-11-23 Baylor College Of Medicine Methods of engineering immune cells having reduced fratricidal activity
US20250222026A1 (en) * 2021-06-08 2025-07-10 Beijing Meikang Geno-Immune Biotechnology Co., Ltd. Cd7-based humanized chimeric antigen receptor and use thereof
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
CN118891280A (zh) * 2022-02-17 2024-11-01 上海优替济生生物医药有限公司 经修饰的免疫效应细胞及其用途
CN114560943B (zh) * 2022-02-28 2022-12-16 先进生物(苏州)有限公司 Cd7-car-t细胞及其制备方法和应用
WO2023185256A1 (zh) * 2022-03-29 2023-10-05 中国医学科学院血液病医院(中国医学科学院血液学研究所) 特异性结合cd7的抗体及其在制备嵌合抗原受体中的应用
CN117004603A (zh) * 2022-04-28 2023-11-07 南京北恒生物科技有限公司 一种cd7基因被敲除的工程化免疫细胞及其用途
EP4525927A1 (en) 2022-05-20 2025-03-26 Novartis AG Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
CA3252208A1 (en) 2022-05-20 2023-11-23 Novartis Ag ANTIBODY-DRUG CONJUGATES
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
EP4559937A1 (en) * 2023-11-24 2025-05-28 Universitat de Barcelona Cd7 targeting moieties for the treatment of cd7 positive cancer
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2304208A1 (en) 1997-09-19 1999-03-25 Dana-Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
AU2002361390A1 (en) * 2001-12-14 2003-06-30 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Anti-cd7 immunotoxin as fusion protein
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP2008518021A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 感染の治療および予防のためのｅｐｈａ２およびｅｐｈｒｉｎａ１のモジュレーターの使用
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
KR101805140B1 (ko) 2007-03-01 2017-12-05 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
EP2185574B1 (en) 2007-09-07 2013-05-08 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN104159909A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法
MY189533A (en) 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093831A2 (en) * 2012-12-14 2014-06-19 Thomson Reuters (Markets) Llc Dynamic function builder
KR101521224B1 (ko) * 2012-12-20 2015-05-19 한양대학교 산학협력단 T 세포 특이적인 인간화 단일조각항체 전달체
MX2015008329A (es) 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
KR102417657B1 (ko) 2013-02-06 2022-07-07 안트로제네시스 코포레이션 개선된 특이성을 갖는 변경된 t 림프구
KR102363191B1 (ko) 2013-02-26 2022-02-17 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
RU2727447C2 (ru) 2013-05-13 2020-07-21 Селлектис Cd19-специфический химерный антигенный рецептор и его применения
EP3309248B1 (en) 2013-05-29 2021-06-09 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
KR102308597B1 (ko) 2013-10-17 2021-10-01 내셔널 유니버시티 오브 싱가포르 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체
EP3071222B1 (en) 2013-11-21 2020-10-21 UCL Business Ltd Cell
CA2937711C (en) 2014-02-14 2020-10-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
MX370272B (es) 2014-03-19 2019-12-09 Cellectis Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
CN107109368A (zh) 2014-10-07 2017-08-29 塞勒克提斯公司 用于调节car诱导的免疫细胞活性的方法
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
PL3253865T3 (pl) 2015-02-06 2022-10-10 National University Of Singapore Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych
IL254141B (en) * 2015-02-27 2022-07-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) focusing on hematological malignancies, preparations and methods for their use
EP3089761B1 (en) 2015-03-02 2019-06-12 Innovative Cellular Therapeutics Co., Ltd. Reducing immune tolerance induced by pd l1
GB201507104D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
US20180371052A1 (en) * 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
WO2017213979A1 (en) 2016-06-06 2017-12-14 St. Jude Children's Research Hospital Anti-cd7 chimeric antigen receptor and method of use thereof
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
CN109996811A (zh) 2016-08-03 2019-07-09 约翰·F·迪帕西奥 用于用嵌合抗原受体治疗t细胞恶性肿瘤的car-t细胞的基因编辑
JP7778468B2 (ja) 2016-11-22 2025-12-02 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断
SG11202000402PA (en) 2017-08-10 2020-02-27 Nat Univ Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
US20210395779A1 (en) 2018-11-14 2021-12-23 Medisix Therapeutics Pte Ltd. Two-gene vectors for generating car-t cells and uses thereof

Also Published As

Publication number Publication date
AU2017363278B2 (en) 2022-10-27
WO2018098306A1 (en) 2018-05-31
KR102889007B1 (ko) 2025-11-21
AU2025205147B2 (en) 2025-09-11
AU2017363278A1 (en) 2019-05-23
AU2022268355A1 (en) 2023-02-09
US11945865B2 (en) 2024-04-02
AU2022268355B2 (en) 2025-04-10
EP3545082A1 (en) 2019-10-02
US20220348655A1 (en) 2022-11-03
CN118581046A (zh) 2024-09-03
US20240182567A1 (en) 2024-06-06
JP2025065142A (ja) 2025-04-17
CA3043752A1 (en) 2018-05-31
CN118562882B (zh) 2025-08-08
EP3545082A4 (en) 2020-07-01
KR20190085528A (ko) 2019-07-18
US11440958B2 (en) 2022-09-13
CN110268049A (zh) 2019-09-20
WO2018098306A8 (en) 2018-08-23
AU2025205147A1 (en) 2025-07-24
US20180148506A1 (en) 2018-05-31
JP2023059873A (ja) 2023-04-27
KR20240099512A (ko) 2024-06-28
CN110268049B (zh) 2024-06-14
SG10201912387PA (en) 2020-02-27
US10550183B2 (en) 2020-02-04
JP7778468B2 (ja) 2025-12-02
CN118562882A (zh) 2024-08-30
JP2019536480A (ja) 2019-12-19
US20180179280A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201903304YA (en) IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201807794VA (en) Naphthene-containing distillate stream compositions and uses thereof
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers